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1 Highlights 
 
 Treatment of sleep disordered breathing in chronic heart failure patients with auto-servo 
ventilation (ASV) reduced sleep fragmentation measured by polysomnography. 
 
 Seep fragmentation and sleep efficiency, measured by actigraphy at home, significantly 
improved after 12 weeks of ASV therapy. 
 
 The effects of ASV were similar in predominantly central or obstructive sleep apnea. 
 
ABSTRACT 
 
Background: Impaired sleep efficiency is independently associated with worse prognosis in patients 
with chronic heart failure (CHF). Therefore, we tested whether auto-servo ventilation (ASV, BiPAP-
ASV, Philips Respironics) reduces sleep fragmentation and improves sleep efficiency in CHF patients 
with central sleep apnea (CSA) or obstructive sleep apnea (OSA). 
Methods: In this multi-center, randomized, parallel group trial 63 CHF patients (age 64±10 y; left 
ventricular ejection fraction 29±7%) with CSA or OSA (Apnea-Hypopnea Index, AHI 47±18/h; 46% 
CSA) referred to sleep laboratories of the four participating centers were studied. Participants were 
randomized to either ASV (n=32) or optimal medical treatment alone (control, n=31). 
Results: Polysomnography (PSG) and actigraphy at home (home) with centralized blinded scoring 
were obtained at baseline and 12 weeks. ASV significantly reduced sleep fragmentation (total arousal 
indexPSG: -16.4±20.6 versus -0.6±13.2/h, p=0.001; sleep fragmentation indexhome: -7.6±15.6 versus 
4.3±13.9/h, p=0.003, respectively) and significantly increased sleep efficiency assessed by actigraphy 
(SEhome) compared to controls (2.3±10.1 versus -2.1±6.9%, p=0.002). Effects of ASV on sleep 
fragmentation and efficiency were similar in patients with OSA and CSA. 
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Conclusions: In CHF patients with either CSA or OSA, ASV treatment modestly improves sleep 
fragmentation as well as sleep efficiency at home.  
 
 
Key words: heart failure, sleep disordered breathing, auto-servo ventilation, sleep quality, NT-pro 
BNP 
 
Clinical Trial Registration: http://www.controlled-trials.com/ISRCTN04353156    
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2 INTRODUCTION 
 
Chronic heart failure (CHF) affects 1-2% of the adult population and prevalence increases up to 4-
16% in patients over 55 years [1–4]. Central sleep apnea (CSA) and obstructive sleep apnea (OSA) are 
reported in 25–40% and 49-72% of CHF patients respectively [5–8]. Patients with CHF have a 
significantly shorter sleep duration and reduced sleep efficiency (SE) assessed by polysomnography 
(PSG) compared to individuals from a community sample whether or not they have OSA [9]. There 
are two reasons, why sleep fragmentation and sleep may be important treatment targets in CHF 
patients with sleep disordered breathing (SDB). First, patients with CHF have poor SE and SE 
assessed by PSG is a strong predictor for mortality in CHF patients, independent of other known risk 
factors for mortality [10]. Secondly, high SE early after initiation of continuous positive airway 
pressure (CPAP) in patients with OSA without known heart disease is an important factor in 
determining their subsequent use of this treatment modality [11,12]. 
In patients with CHF, concomitant sleep disorders such as insomnia, periodic limb movement 
disorder, sleep disturbances either as a consequence of depression or due to the presence of CHF per 
se are often difficult to manage [13,14]. Therefore, CSA or OSA which can be treated with positive 
airway pressure (PAP) are promising targets for improving sleep fragmentation and sleep quality in 
CHF [15].  
It remains unclear if treatment of CSA with PAP in patients with CHF can improve sleep 
fragmentation and sleep quality. In OSA patients with normal cardiac function, PAP-therapy leads to a 
significant reduction of sleep fragmentation and an increase of the time in sleep stage N3 as well as 
REM sleep [16]. In CHF patients with sleep apnea, especially with CSA, the effects of PAP therapy on 
sleep structure are rather unclear. There are only a few randomized studies addressing this issue in 
patients with CHF and CSA and/or OSA. In the largest trial, a subanalysis of the CANPAP study with 
205 HF patients, the effects of CPAP on CSA were determined. Apnea-hypopnea-index (AHI) was 
significantly reduced, but neither arousal frequency nor sleep structure changed significantly [17]. 
Studies of auto-servo ventilation (ASV) in CHF patients with CSA and/or OSA report conflicting 
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effects on sleep fragmentation and sleep quality, assessed by polysomnography. Whilst two studies 
reported a reduction of arousal frequency and restoration of sleep structure within the first night of 
ASV treatment in CHF patients with CSA [9,18], another study showed that treatment of CSA with 
ASV in CHF patients significantly improved CSA and OSA, but had no effect on arousal frequency 
[19]. In these studies, sleep quality was assessed by PSG in a sleep laboratory when CPAP or ASV 
were used throughout a single night. This does not reflect the time of use of the PAP device and 
effects on sleep fragmentation and SE at home over a longer period of time.  
We tested if ASV (BiPAP-ASV, Philips Respironics) reduces sleep fragmentation and improves SE as 
assessed by in-lab PSG and also home actigraphy in patients with severe CSA or OSA. 
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3 METHODS 
 
3.1 Design and participants 
We analyzed in a multi-center, randomized, rater-blinded, open label, parallel group trial 
(ISRCTN04353156), the effects of ASV on arousals, sleep efficiency and sleep stages (assessed by 
PSG) and sleep fragmentation and sleep efficiency (assessed by actigraphy) [20]. Such analyses were 
not pre-specified. The pre-specified primary and secondary outcomes of the trial (ISRCTN04353156) 
were previously published [20]. In patients with CHF and SDB, ASV reduced NT-proBNP levels, but 
improvement of left ventricular ejection fraction (LVEF) or quality of life was not greater than in the 
control group [20].  
The study complies with the Declaration of Helsinki. The protocol was approved by the local ethics 
committees, and all patients provided written informed consent. Inclusion criteria were a medical 
history of CHF due to ischemic, non-ischemic or hypertensive cardiomyopathy, age 18-80 years, 
impaired exercise capacity (New York Heart Association, NYHA, Class II or III), impaired LVEF  
40%, stable clinical status, and stable optimal medical therapy according to the guidelines of the 
European Society of Cardiology [21] for at least 4 weeks and an AHI  20 per hour of sleep assessed 
by in-laboratory PSG [22,23]. 
Exclusion Criteria were unstable angina, myocardial infarction, cardiac surgery or hospital admissions 
within the previous 3 months, NYHA Class I or IV, pregnancy, contraindications for BiPAP AutoSV, 
patients receiving oxygen therapy, severe restrictive and obstructive airways disease, CHF due to 
primary valve disease, patients awaiting heart transplant, inability or unwillingness to provide written 
informed consent, and diurnal symptoms of OSA requiring immediate treatment e.g. falling asleep 
while driving. 
  
3.2 Randomization and Intervention  
Eligible patients were randomized 1:1, either to receive optimal medical management or optimal 
medical management plus ASV therapy (BiPAP-ASV, Philips Respironics). Randomization was 
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performed by a computerized schedule in random blocks of four and was stratified by type of sleep 
apnea (e.g. OSA and CSA) [20]. Details of the initiation of ASV have been described previously [20].  
 
 
3.3 Outcome measures 
3.3.1 Polysomnography (PSG) 
PSG was performed at a screening visit, at ASV initiation to ensure abolition of the AHI and after 12 
weeks follow up. At follow up patients in the control group received diagnostic PSG, whereas patients 
in the ASV group received PSG during ASV treatment [20]. Airflow and thoraco-abdominal effort 
were recorded quantitatively by nasal pressure cannula and respiratory inductance plethysmography 
[9]. Sleep stages, apneas, hypopneas and arousals were measured, defined and scored by two 
experienced sleep technicians who were blinded to group status according to standard diagnostic 
criteria. Apneas were defined as absence of airflow 10 second (measured reduction of airflow to less 
than 10% peak ‘nominal’ airflow). Hypopneas were defined as a  50% reduction in airflow from 
baseline for 10 seconds or with a discernable reduction in airflow, if it was in association with a 4% 
oxygen desaturation or an arousal. Apneas and Hypopneas had to be classified obstructive if out-of-
phase thoraco-abdominal motion or airflow limitations were present. Mixed apneas were classified as 
central through the study. The apnea-hypopnea index (AHI) was defined as the number of apneas and 
hypopneas per hour of sleep. Patients with ≥50% of all apneas and hypopneas being central in nature 
were classified as having CSA. Patients with a proportion <50% of central apneas and hypopneas were 
classified as having OSA. Arousals were defined as a cortical response to stimulus characterized by at 
least a 3 second increase in EEG frequency: the appearance of alpha or beta rhythm, an obvious 
change to an ascending sleep stage, in REM sleep as an increase in submental EMG or the appearance 
of a K-complex, regardless of sleep stage. The arousal was classified as an respiratory arousal, when it 
occurred during or 1 second after an apnea or hypopnea. The arousal was classified as a movement 
arousal, when it occurred 1 second before or after the leg movement. Total arousals contained 
respiratory arousals, movement arousals and spontaneous arousals [24].  For subanalyses of arousals 
data from one study site were available (n=18). SE assessed by PSG (SEPSG) was defined as the ratio 
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of total sleep time to time in bed. To ensure quality control, a blinded analysis of each sleep study was 
centralized and performed by two experienced sleep technicians at the University of Pennsylvania. 
 
3.3.2 Actigraphy  
Compared to the “gold standard” polysomnography in sleep laboratory, wrist actigraphy was shown to 
be a reliable method to evaluate sleep fragmentation and sleep quality in the patients` natural 
environment at home [25]. The participants were asked to wear an Actiwatch® (Model AW64; 
Cambridge Neurotechnology Ltd, Cambridge, UK) on their non-dominant wrist for 5 days prior to 
therapy titration and during the last 7 days of their 12 weeks of therapy. Participants also used the 
event marker of their Actiwatch® to mark sleep times.  
The Actiwatch® measured activity with a piezo-electric accelerometer that recorded intensity, amount 
and duration of movement in all directions. All movements over 0.05g were recorded with a sampling 
frequency of 32 Hz. Actigraph data from 1-min epochs were collected and automatic scoring of sleep 
was performed using a validated algorithm. This algorithm analysed recorded activity counts in each 
epoch according to the level of activity in the surrounding 2 min (2 min) to give a final activity count 
for each epoch. The total value was used to decide if the epoch was scored as wake or sleep. A 
threshold of >40 counts/epoch was used to define wake.  
Time in bed, sleep latency, SE assessed by actigraphy (SEhome) and sleep fragmentation indexhome 
were all calculated by the actigraphy sleep–wake algorithm. To ensure quality control, the final 
blinded analysis of each participant’s actigraphy recording was centralised to one investigator.  
 
 
3.4 Statistical Analysis  
The intention to treat (ITT)-analysis set contained all randomized patients. For all statistical analysis 
we used the ITT set. Only to analyse the association of the change of SE, sleep fragmentation and the 
changes in cardiac function (NT-pro BNP) the Per-Protocol (PP)-set was used. In the PP-set, patients 
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with changes in cardiac medication and patients who prematurely withdrew from the study were 
excluded [20]. 
The baseline characteristics were tested with the two-sided independent samples t-test at the 5% 
significance level. Further statistical tests were performed for the between group differences of the 
change in value within twelve weeks of treatment using analysis of covariance (ANCOVA) 
accounting for possible baseline differences. Changes throughout the study within one group were 
assessed with the paired samples t-test. All statistical analyses were performed with SPSS version 
18.0.  
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4 RESULTS 
 
4.1 Trial Flow 
A total of 194 patients were screened for eligibility as described previously [20]. Most of them were 
excluded because they did not fulfil the inclusion criteria of AHI ≥ 20 per hour of sleep or LVEF  
40%. 72 patients were randomized, 37 patients to the ASV group and 35 patients to the control group. 
In the ASV and control groups 5 of 37 patients and 4 of 35 patients were lost to follow-up (11% versus 
14%, p=0.252), respectively. Therefore, the ITT-analysis set contained 32 patients in the ASV and 31 
patients in the control group (Figure1). The PP-set contained 21 patients in the ASV and 21 patients in 
the control group. 
 
 
 
 
4.2 Participants 
Table 1 shows the baseline characteristics of the ASV and the control group. There was a 
predominance of males with an average age of 64 years. Body Mass Index (BMI) in the control group 
was significantly higher than in the ASV group. Resting blood pressure and heart rate, LVEF, NYHA-
Classification and NT-pro BNP concentrations, as well as the proportion of ischemic heart failure, 
were similar.  
In the ASV group the EPAP was 8.1±1.5 cmH2O, the minimum IPAP was 8.7±2.2 cmH2O and the 
maximum IPAP was 17.0±2.7 cmH2O. Average usage of ASV per night was similar during the first 
night at the sleep lab, the 12 week treatment period “at home” as well as during the follow-up PSG at 
12 weeks (4.33±3.25 hours versus 4.45±2.90 hours versus 4.72±3.28 hours, p=0.751).  
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4.3 Polysomnography 
Patients in both groups had severe sleep apnea (Table 2). The proportion of CSA was 47% in the ASV 
and 45% in the control group. There was no significant difference in AHI, cAHI and time in Cheyne 
Stokes Respiration in the control and the ASV group at baseline (p=0.572, p=0.777 and p=0.616, 
respectively). After 12 weeks, patients in the ASV group showed a significantly greater reduction of 
AHI, central AHI and obstructive AHI compared to the control group. The duration of Cheyne Stokes 
Respiration was significantly reduced with ASV (Table 2). Mean oxygen saturation significantly 
improved in the ASV group compared to the control group (p=0.001). Furthermore the total arousal 
index was significantly improved in the ASV group compared to the control group (Table 2, Figure 
2A). There was no difference in the change in SEPSG between baseline and 12 weeks neither in the 
ASV group nor in the control group (Table 2, Figure 2B). There was no linear correlation between 
average ASV usage and changes of total arousal index or SEPSG (Pearson correlation R=0.313, p=0.498 
and R=0.093, p=0.631, respectively). Even when distinguishing between “compliant” patients (usage 
of the ASV more than 4 hours per night) and “non-compliant patients” (usage less than 4 hours) there 
was no significant difference in change of arousal index (-14/h vs. -19/h, p=0.538) or SEPSG (0.5% vs. -
0.9%, p=0.755). 
Analysis of sleep stages at baseline and after 12 weeks showed a significant reduction of time in sleep 
stage N1 paralleled by a statistically non-significant increase of sleep stage N2 and REM sleep in the 
ASV group compared to the control group. The control group had no significant change in the 
distribution of sleep stages (Table 2, Figure 3).  
Changes in PSG parameters in the ASV group were independent of the type of sleep apnea. Patients 
with OSA (n=17) showed similar reductions of total arousal index and SEPSG as patients with CSA 
(n=15, p=0.792, p=0.224, respectively).  
Subanalyses of arousals from one study site showed the effects of ASV on respiratory, movement and 
sponataneous arousals, respectively. The majority of arousals fulfilled the criteria of respiratory 
arousals. ASV significantly reduced respiratory arousal index and total arousal index (Table 3). 
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4.4 Actigraphy  
At baseline there were no significant differences between the ASV group and control group in sleep 
onset latency (p=0.693), total sleep time (p=0.792), time in bed (p=0.480), sleep fragmentation index 
(p=0.770) and SEhome (p=0.372, Table 4). After 12 weeks, participants randomized to ASV therapy 
showed a significantly greater reduction of sleep fragmentation index and a significantly better SEhome 
at night than patients in the control group (Table 4, Figure 2). Change of sleep onset latency and total 
sleep time were similar in both groups (Table 4). The changes of sleep fragmentation and SEhome in the 
ASV group were not associated with changes in the Epworth Sleepiness Scale (p=0.338 and p=0.645, 
respectively). There was no linear correlation between average ASV usage and changes of sleep 
fragmentation or SEhome (Pearson correlation R=0.092, p= 0.630 and R=-0.072, p=704, respectively). 
And there was no significant statistically difference between “compliant” patients and “non-compliant 
patients” regarding changes of sleep fragmentation (-8/h vs. -8/h,  p=0.971) or SEhome (1.7% vs. 3.2%, 
p=0.686). 
 
 
 
4.5 NT-pro BNP 
NT-pro BNP tended to decrease more in the ASV group compared to the control group (p=0.062 after 
adjustment for baseline differences). The change of NT-pro BNP in the ASV group from baseline to 
12 weeks was not associated with the change in AHI neither in the ITT-analysis (R
2
=0.024) nor in the 
PP-analysis (R
2
=0.073). Using the PP-set the change of NT-pro BNP was significantly associated with 
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changes in surrogates of sleep quality in the home environment such as actigraphically assessed sleep 
fragmentation index (R
2
=0.395, p=0.002) and SEhome (R
2
=0.418, p=0.002). 
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5 DISCUSSION 
 
The current subanalysis of the trial “ASV in CHF with sleep SDB - a randomized controlled trial” 
(ISRCTN04353156) [20] dealt with the effects of ASV on sleep quality and leads to several novel 
observations. First, CHF patients treated with ASV had a significant decrease of sleep fragmentation 
compared to the control group, indicated by a reduction of total arousal frequency assessed by PSG. 
Second, sleep fragmentation and SE, measured by actigraphy at home, also significantly improved 
after 12 weeks of ASV therapy. Third, the effects of ASV on measures of sleep fragmentation and 
efficiency assessed by PSG were similar in CHF patients with predominantly CSA or OSA. In a post-
hoc analysis, the changes of surrogates of sleep fragmentation and quality in the home environment 
were significantly associated with an improvement of NT-proBNP concentrations in patients with 
ASV therapy. 
The data of the present analysis have to be interpreted in the light of the preliminary results of the 
SERVE-HF study [26] (ISRCTN19572887), a multinational, multi-center, randomized controlled trial 
designed to assess whether treatment of predominantly CSA with ASV therapy reduces mortality and 
morbidity in patients with CHF. The preliminary primary results showed a statistically significant 2.5 
percent absolute increased annual risk of cardiovascular mortality for those randomized to ASV 
therapy compared to the control group [27,28]. Mechanism explaining this unexpected result remain 
unclear. Malhotra et al remark in their comment that the new results should not be seen as a 
disappointment, they strongly support further investigation in this area [29]. 
In our study, treatment of sleep apnea in CHF patients with ASV reduced total arousal frequency by 
approximately 39%, while there was no change in the control group. This magnitude of improvement 
is similar to other randomized trials [30,31]. Randerath et al showed in a long term study of ASV in 
patients with CHF and coexisting CSA and OSA a reduction of arousal frequency of 35% after 12 
month ASV treatment [30]. Yoshihisa et al, also found a reduction of arousal frequency of 37% in 
patients with CHF and CSA treated with ASV [31].
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In our study, SE measured by PSG did not change after 3 month of ASV treatment. There are no other 
randomized trials of ASV evaluating its effects on SE after more than one night of treatment. Arzt and 
Teschler observed an improvement of SE after treatment of severe CSA in 14 CHF patients with ASV 
[9,18]; while other studies showed no significant change in SE [32,33]. In the ASV group, there was a 
decrease of sleep stage N1 and a shift to sleep stage N2 and REM sleep after 12 weeks, while there 
was no significant change in sleep stages in the control group. This is consistent with other studies 
evaluating ASV treatment in CHF patients with CSA. Most of them reported a decrease of sleep stage 
N1 and N2, as well as an increase of sleep stage N3 and REM sleep [9,18,30,31,34].  
The results of actigraphy at home showed a significant improvement of sleep fragmentation in the 
ASV group compared to the control group. This is in line with our overnight laboratory PSG findings, 
where a significant decrease of total arousal frequency in the ASV group was observed. Those 
receiving ASV therapy had no changes in SE as measured by PSG, whereas wrist actigraphy showed a 
significant improvement of SE after 12 weeks may be due to discrepancy between the 2 measuring 
devices.  
Studies in patients with OSA without overt heart disease showed that wrist actigraphy has a high 
agreement with PSG results [28,35], although a few studies report an overestimation of TST and 
therefore SE in actigraphy [36]. Laboratory PSG measures only one night of sleep and in an artificial 
environment whereas less intrusive actigraphy, measures sleep over several days/nights and in the 
patient´s home. The changes in sleep quality in the ASV group were not associated with changes in the 
Epworth sleepiness scale. This may be due to the fact, that both groups had no excessive sleepiness at 
baseline, as prescribed previously [23]. 
Until now, there are no studies comparing the effects of ASV treatment in CHF patients with either 
CSA or OSA. In our study 15 patients in the ASV group had OSA while 14 patients had 
predominantly CSA. The improvements with ASV in CHF patients on sleep fragmentation and SE 
were similar in those with predominantly CSA or OSA. Regardless of the type of sleep apnea the 
reduction in arousal frequency on ASV treatment in our participants was less than that reported in 
studies of PAP therapy in patients without cardiac disease. In contrast to OSA patients without cardiac 
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disease [16,37] PAP or ASV treatment does not normalize sleep architecture, e.g. slow wave sleep 
remains significantly reduced. Therefore other factors may contribute to reduced sleep quality in CHF 
patients, such as medication side effects (e.g. beta blockers), pulmonary congestion or higher rates of 
concomitant comorbidities including periodic leg movement disorder, insomnia or depression 
[13,14,38]. 
Consistent with other randomized trials of ASV in CHF patients with SDB, we showed a greater 
reduction of NT-proBNP compared to the control intervention [9,30,39,40]. Using the PP-set, in the 
ASV group the reduction of NT-proBNP was significantly associated with a reduction of sleep 
fragmentation and an increase of SE assessed with actigraphy.  
Patients in the control group had a significantly higher BMI and higher use of diuretics than patients in 
the ASV group. In the context of findings that nocturnal rostral fluid can contribute to the 
pathogenesis of both OSA and central sleep apnea [41] in patients with heart failure by accumulation 
in the neck or in the lungs, respectively, this difference may have an influence on the severity and type 
of SDB. However, in the present study the AHI, the central AHI as well as the time in Cheyne Stokes 
Respiration were similar between groups.  
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6 CONCLUSIONS 
In summary, we showed that ASV therapy in patients with CHF and severe CSA or OSA can reduce 
sleep fragmentation and may improve sleep quality. The effects of ASV on sleep fragmentation and 
sleep quality are modest. Whether such effects translate in improved subjective sleep quality and 
quality of life, merits further investigation.   
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Figure 1. Flow chart. Abbreviations: CV - Cardiovascular; ASV – Auto-Servo Ventilation. Figure 1.5 
column fitting 
 
Figure 2. Effects of Auto-Servo Ventilation (ASV) in patients with CHF and severe CSA or OSA on 
sleep fragmentation and sleep efficiency (SE). (a) ASV (white) significantly reduced the total arousal 
index assessed by PSG (Arousal IndexPSG) and the sleep fragmentation index assessed by actigraphy at 
home (Sleep Fragmentation Indexhome) compared to the control group (black). (b) While ASV had no 
significant effect on SE assessed by PSG, ASV significantly increased SE assessed at home by 
actigraphy compared to the control group. Each figure single column fitting. 
 
Figure 3. Percent changes in the distribution of sleep stage in the control group (black) and the ASV-
group (white). In the control group the distribution of sleep stages remained similar after 12 weeks. In 
the ASV group there was a significant reduction of sleep stage 1 (N1) and a redistribution to sleep 
stage N2 and rapid eye movement sleep (REM) was observed. Abbreviations: N1= sleep stage N1, 
N2=sleep stage N2, N3=sleep stage N3, REM=rapid eye movement sleep. Figure 1.5 column fitting 
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Table 1 Baseline Characteristics 
 Control 
N=31 
ASV 
N=32 
p-value 
Age, years 65±9 64±10 0.636 
Male, n (%) 28 (90) 30 (94) 0.615 
BMI, kg/m2 32±5 29±4 0.026 
Glomerular Filtration Rate, ml/min/1.73m
2
 68±22 67±19 0.859 
NT-pro BNP, ng/ml 1259±1430 1050±1084 0.517 
Left ventricular ejection fraction, % 29±6 29±7 0.971 
NYHA-Class II, n (%) 
NYHA-Class III, n (%) 
25 (81) 
6 (19) 
24 (75) 
8(25) 
0.590 
Cause of Heart Failure 
  Ischaemic, n (%) 
  Idiopathic, n (%) 
  Hypertensive, n (%) 
 
19 (61) 
10 (32) 
2 (7) 
 
16 (50) 
16 (50) 
0 (0) 
 
0.163 
Rhythm & Pacing 
  History of Atrial Fibrillation, n (%) 
  Bi-ventricular Pacemaker, n (%) 
  Implanted Cardiac Defibrillator, n (%) 
 
6 (19) 
5 (16) 
15 (48) 
 
6 (19) 
2 (6) 
16 (50) 
 
0.277 
0.257 
0.898 
Medication 
  Loop diuretic, n (%) 
  Spironolactone, n (%) 
  ACE-inhibitor, n (%) 
  AT-receptor blocker, n (%) 
  Beta-receptor blocker, n (%)  
 
28 (90) 
15 (48) 
20 (65) 
9 (29) 
28 (90) 
 
20 (63) 
16 (50) 
24 (75) 
10 (31) 
25 (78) 
 
0.010 
0.898 
0.365 
0.848 
0.185 
Data are presented as mean±SD unless otherwise stated.  ASV – Auto-Servo Ventilation;  n - number;  
BMI - Body Mass Index; NT-pro BNP – N Terminal-pro B-type natriuretic peptide, NYHA – New 
York Heart Association; ACE - Angiotensin-Converting Enzyme; AT - Angiotensin.  
 
 
Table 2 Outcome measures polysomnography 
 
Control 
N=31 
ASV 
N=32 
ANCOVA 
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Polysomnography baseline 12 weeks p-value baseline 12 weeks p-value p-value* 
Sleep onset latency (min) 21±19 18±17 0.353 18±16 13±11 0.132 0.244 
Time In Bed (min) 474±53 474±41 0.937 464±39 460±60 0.701 0.427 
Total Sleep Time (TST, min) 327±92 327±78 0.998 376±59 374±77 0.907 0.711 
Apnea-Hypopnea Index (AHI, /h) 46±19 47±22 0.814 50±18 10±10 < 0.001 < 0.001 
Central AHI (/h) 19±15 20±15 0.651 21±16 5±5 < 0.001 < 0.001 
Cheyne Stokes Respiration (min) 62±51 60±58 0.702 74±77 16±18 < 0.001 < 0.001 
Total Arousal Index (/h) 41±17 41±20 0.824 45±16 29±18 < 0.001 0.002 
Sleep efficiency (%) 68±15 69±15 0.823 74±10 75±12 0.933 0.687 
Sleep Stage N1 (% TST) 21±16 23±20 0.337 23±13 14±8 0.001 0.002 
Sleep Stage N2 (% TST) 65±13 63±17 0.671 62±12 69±9 0.016 0.058 
Sleep Stage N3 (% TST) 3±6 2±6 0.323 0.3±0.8 0.9±3.3 0.306 0.502 
Rapid Eye Movement Sleep  
(REM, % TST) 
12±9 11±8 0.696 15±6 16±8 0.273 0.057 
Data is presented as mean±SD. *P-value for the between group differences, adjusted for baseline 
differences using analysis of covariance (ANCOVA) 
 
Table 3 Effect of ASV on arousals from sleep*  
 
Control 
N=10 
ASV 
N=8 
ANCOVA 
Polysomnography baseline 12 weeks p-value baseline 12 weeks p-value p-value
†
 
Respiratory Arousal Index (/h) 28±14 27±23 0.825 35±13 6±7 <0.001 0.001 
Movement Arousals Index (/h) 0.3±0.6 0.4±0.5 0.891 2±5 5±7 0.308 0.143 
Spontaneous Arousals Index (/h) 14±5 17±9 0.299 12±7 16±5 0.193 0.752 
Total Arousals Index (/h) 42±13 45±26 0.705 50±16 26±14 0.001 0.013 
*Classification of arousals in respiratory, movement and spontaneous arousals were available from 
one study site (n=18). 
†
P-value for the between group differences, adjusted for baseline differences using analysis of 
covariance (ANCOVA).  
 
 
Table 4 Outcome measures actigraphy 
 
Control 
N=31 
ASV 
N=32 
ANCOVA 
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Actigraphy baseline 12 weeks p-value baseline 12 weeks p-value p-value* 
Sleep Latency (min) 32±33 39±40 0.092 29±28 26±18 0.606 0.080 
Time In Bed (min) 527±68 539±74 0.139 522±78 510±78 0.281 0.053 
Total Sleep Time (min) 372±57 368±60 0.651 390±84 393±67 0.844 0.265 
Sleep Fragmentation Index (/h) 46±15 50±19 0.104 46±21 38±14 0.012 0.001 
Sleep Efficiency (%) 71±10 69±11 0.118 75±12 77±9 0.211 0.005 
Data are presented as mean±SD. *P-value for the between group differences, adjusted for baseline 
differences using analysis of covariance (ANCOVA) 
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